Accessibility Menu
 
Rhythm Pharmaceuticals logo

Rhythm Pharmaceuticals

(NASDAQ) RYTM

Current Price$88.48
Market Cap$6.20B
Since IPO (2017)+202%
5 Year+301%
1 Year+50%
1 Month+3%

Rhythm Pharmaceuticals Financials at a Glance

Market Cap

$6.20B

Revenue (TTM)

$217.16M

Net Income (TTM)

$202.68M

EPS (TTM)

$-3.14

P/E Ratio

-28.85

Dividend

$0.00

Beta (Volatility)

1.22 (Average)

Price

$88.48

Volume

6,044

Open

$91.11

Previous Close

$90.52

Daily Range

$88.48 - $91.25

52-Week Range

$58.71 - $122.20

RYTM: Motley Fool Moneyball Superscore

67

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Rhythm Pharmaceuticals

Industry

Biotechnology

Employees

414

CEO

David P. Meeker, MD

Headquarters

Boston, MA 02116, US

RYTM Financials

Key Financial Metrics (TTM)

Gross Margin

89%

Operating Margin

-91%

Net Income Margin

-93%

Return on Equity

-286%

Return on Capital

-58%

Return on Assets

-46%

Earnings Yield

-3.47%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$6.20B

Shares Outstanding

68.53M

Volume

6.04K

Avg. Volume

870.72K

Financials (TTM)

Gross Profit

$170.26M

Operating Income

$192.02M

EBITDA

$174.12M

Operating Cash Flow

$115.67M

Capital Expenditure

$953.00K

Free Cash Flow

$116.63M

Cash & ST Invst.

$388.95M

Total Debt

$246.47M

Rhythm Pharmaceuticals Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$60.11M

+83.8%

Gross Profit

$52.95M

+82.3%

Gross Margin

88.09%

N/A

Market Cap

$6.20B

N/A

Market Cap/Employee

$21.92M

N/A

Employees

283

N/A

Net Income

$55.64M

-12.4%

EBITDA

$52.36M

-20.0%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Net Cash

$113.61M

-63.4%

Accounts Receivable

$34.19M

+91.8%

Inventory

$28.65M

+48.3%

Long Term Debt

$216.21M

+5532.0%

Short Term Debt

$10.81M

+4724.1%

Return on Assets

-45.82%

N/A

Return on Invested Capital

-58.20%

N/A

Free Cash Flow

$44.19M

-9.5%

Operating Cash Flow

$44.19M

-9.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PTGXProtagonist Therapeutics, Inc.
$102.00-0.18%
ACLXArcellx, Inc.
$115.07+0.02%
NUVLNuvalent, Inc.
$100.95-1.32%
AKROAkero Therapeutics, Inc.
$54.65+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$14.70-0.02%
TET1 Energy Inc.
$6.61+0.17%
POETPoet Technologies
$14.64-0.08%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$43.03+0.00%

Questions About RYTM

What is the current price of Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals is trading at $88.48 per share.

What is the 52-week range for Rhythm Pharmaceuticals?

Over the past 52 weeks, Rhythm Pharmaceuticals has traded between $58.71 and $122.20.

How much debt does Rhythm Pharmaceuticals have?

As of the most recent reporting period, Rhythm Pharmaceuticals reported total debt of $227.02M.

How much cash does Rhythm Pharmaceuticals have on hand?

Rhythm Pharmaceuticals reported $62.14M in cash and cash equivalents in its most recent financial results.

What is Rhythm Pharmaceuticals’s dividend yield?

Rhythm Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.